Abstract
B-cell Acute Lymphoblastic Leukaemia (B-ALL) is a malignant neoplasm of B-cell precursors in the bone marrow and blood. Next generation sequencing has the potential to improve risk stratification and treatment approaches for B-ALL patients. Using this approach, causative genetic lesions in various kinase and cytokine receptor signalling molecules have been identified, some of which are targetable using rational therapies.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Publication status | Published - Jun 2017 |
| Externally published | Yes |
| Event | Australian Society for Medical Research (ASMR) SA Meeting 2017 - Adelaide, Australia Duration: 26 Jun 2017 → … |
Conference
| Conference | Australian Society for Medical Research (ASMR) SA Meeting 2017 |
|---|---|
| Abbreviated title | ASMR SA Meeting 2017 |
| Country/Territory | Australia |
| City | Adelaide |
| Period | 26/06/17 → … |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Identification
- Cloning
- Lymphoblastic Leukaemia
Fingerprint
Dive into the research topics of 'Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell acute lymphoblastic leukaemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver